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 ABSTRAK
Mutasi telah dikenalpasti berlaku sebelum pembentukan pelbagai jenis kanser. 
Mutasi di dalam gen p53 boleh dijumpai dalam kanser payudara. Objektif kajian 
ini adalah untuk menentukan korelasi antara protein p53 dengan wanita dalam 
usia pra-menopaus. Sebanyak 111 tisu kanser payudara telah dikaji untuk ekspresi 
protein p53 oleh (Immunohistochemistry) ‘IHC’. Hasil kajian mendapati majoriti 
36.9.% (n = 41/111) wanita berumur 41 tahun ke atas yang menghidap kanser 
payudara menunjukkan ekspres p53 protein positif (+) yang lebih banyak dan hanya 
2.7% (n = 3/111) bawah 41 tahun ekspress protein p53 positif (+) berlebihan. Walau 
bagaimanapun, ujian Fishers Exact menunjukkan hubungan yang tidak signifikan 
antara kumpulan umur peserta dengan kategori protein p53 (χ2 (1) = 0.78; p = 0.52); 
Cramer’s V = 0.08; p = 0.37). Anggaran risiko menunjukkan kebarangkalian ekspresi 
protein p53 (+) yang melampau dalam kumpulan yang berusia bawah daripada 41 
tahun adalah 0.66 kali lebih kurang berbanding kumpulan wanita yang berusia 
41 tahun ke atas. Kesimpulannya, dengan atau tanpa ekspresi protein p53 yang 
melampau, wanita yang berusia lebih daripada 41 tahun mempunyai risiko yang 
lebih besar untuk  menghidap kanser payudara.
Kata kunci: ekspresi protein p53, wanita,  umur, pra menopaus, kanser payudara
ABSTRACT
Mutation is known to occur before the development of various types of cancers. 
Mutation in p53 gene can be found in human breast cancer. The aim of the present 
study was to determine the correlation between p53 protein expressions with women 
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increased steadily from the age group 
of 30 yrs and the peak was from 40 to 
59 yrs. In contrast, in Western countries 
a high proportion of patients presented 
with an advanced-stage of cancer. A 
Malaysian women’s cumulative risk 
of breast cancer in her lifetime was 
in the ratio of 1:20 with the highest 
risk in Chinese (1:14) (National Cancer 
Registry Malaysia 2006; Hisham & Yip 
2004). Breast cancer could be caused 
by a diversified modifiable and non-
modifiable risk factors which include 
gender, age, history of benign breast 
or related diseases and reproductive 
factors such as menstrual history, first 
pregnancy’s age, lifestyle, hormonal, 
and genetic factors. 
 Genetic factors in the pathogenesis 
of breast cancer can be ascribed 
to be inherited susceptibility. Three 
genes (p53, BRCA1, and BRCA2) 
were identified, which may alter the 
formation of tumour suppressor genes. 
In breast cancer p53 mutation/alteration 
are reported in  50% of primary 
carcinomas (Callahan 1992; Muller & 
Vousden 2013; Bertheau et al. 2013). 
in premenopausal age. A total of 111 breast cancer tissues were examined for p53 
protein expression by IHC. The results showed that majority (36.9%; n=41/111) 
who were more than 41 yrs, overexpressed positive p53 (+) protein category and 
2.7% (n=3/111) aged 41 yrs and less, showed less positive p53 (+) protein category. 
However, the Fishers exact test, indicated that, there was no significant correlation 
between participant’s age group with p53 protein category (χ2 (1) = 0.78; p =0.52) 
and no correlation strength was indicated (Cramer’s V coefficient = 0.08; p 
=0.37), respectively. The risk estimate showed probability of p53 (+) protein being 
overexpressed in the age group < 41 yrs was 0.66 times less likely compared to the 
age group > 41 yrs. In conclusion, with  or without overexpression of p53 protein, 
women above 41 yrs were found to have greater risk. 
Keywords: age, breast cancer, expression, p53 protein, premenopausal, women
   
INTRODUCTION
Normal breasts or mammary glands 
produce milk. In normal cell cycles, 
proliferation and regression are 
controlled by hormones and growth 
factors. Abnormal cellular changes 
progress from proliferative disease to 
atypical hyperplasia to carcinoma in 
situ to invasive breast cancer. While 
the majority of breast cancers are 
adenocarcinomas occurring in the 
upper outer quadrant, breast cancer is 
a complex and heterogeneous group of 
diseases with distinct morphologic and 
molecular features (Foxson et al. 2011; 
Cado  et al. 2013; Watanabe et al. 2015). 
Over the past century there has been 
a dramatic increase in the pathological 
abnormality of the cases which is referred 
to as cancer.  An American Cancer 
Society (2015) reported that cancer is 
best defined as diseases characterized 
by uncontrollable growth of abnormal 
cells which could spread to other parts 
of the body, and potentially be lethal.
 In Malaysia, the incidence with regard 
to age suggested that the breast cancer 
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The p53 is a tumour suppressor gene 
which responds to the DNA damage 
that induces the pathways for cell 
apoptosis, cell cycle arrest, and DNA 
repair. The function is to maintain the 
genetic integrity of the cells resulting 
p53, as one of the most studied 
proteins in oncology (Steele & Lane 
2005). Previous study by Thompson, 
(2014) reported that the abnormalities 
observed in the p53 gene are common 
and could be the key events in the 
pathogenesis of breast cancer.
 The Clinical Practice Guideline 
(CPG), Ministry of Health Malaysia 
(2003), emphasizes the management 
of breast cancer through reinforcing 
those women whom genetically related 
to higher propensity of deleterious 
mutations in BRCA1, BRCA2, and 
TP53 genes. They are advised for 
genetic counselling by geneticist; 
and genetic testing prior to their early 
detection.  Currently, there is limited 
scientific evidence which proposes the 
evaluation of other genes or specific 
loci in common clinical setting of the 
Ministry of Health for genetic testing 
(MOH & AMM 2003). In diagnosing 
p53 expressions and relationship with 
breast cancer occurrence, an IHC 
analyses must be a warranted design by 
utilizing a statistical analysis. However, 
an IHC analysis cannot be ruled out 
as a useful indicator of prognosis in 
clinical applications of  breast cancer 
(Bartley & Ross 2002; Rolland et al. 
2007).  Detection of p53 protein by IHC 
has been widely used as a surrogate 
marker for p53 mutations. Even though, 
the lacking of p53-binding domain 
was noted, the physiological activities 
were dependent on p53 in which, 
the binding to wild-type MDM2 was 
responsible for cancer pathophysiology 
(Inoue  et al. 2016). Secondary cancer 
prevention is a set of intervention that 
uses screening tests or examinations 
which leads to the discovery, control of 
cancerous and precancerous processes. 
A study by  Loud et al. (2002) stated 
that pathophysiological alteration and 
possible counteraction mechanism 
of breast cancer should be first well 
understood.
 In the present study, the main aim 
was to determine the specific patterns 
in breast cancer (BC) risk factors by p53 
status and identifying the way forward, 
in screening for early detection. A 
study by Maas et al. (2016) stated that 
30 yrs women in the United States may 
develop invasive breast cancer at the 
rate of 11.3% by the age of 80 yrs. In 
addition, the proposed model which 
accounted for the risk factors depicted 
4.4% - 23.5% of the average absolute 
risk in bottom and top deciles of the 
risk distribution in women. Apparently, 
women who fell in the lowest and 
highest deciles of non-modifiable 
risk factors accounted for 5th and 9th 
percentile range of the risk distribution 
related to modifiable factors and were 
recorded as 2.9% - 5.0% and 15.5% 
- 25.0%, respectively. Consequently, 
women who were at the highest decile 
of risk pertaining to non-modifiable 
risk factors, low BMI, non-alcoholic 
and non-smoker, and never used 
MHT had higher risks comparable to 
general population of average woman. 
According to Maas et al. (2016) that 
highlighted traditionally, the etiology and 
pathophysiology of breast cancer were 
similarly reported globally. However, 
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the differences in genetic materials of 
Asian women could possibly triggers 
the difference interaction mechanism 
with environmental exposure.  This may 
include reproductive risk factors and 
dietary factors that may be involved in 
alteration of the susceptibility towards 
beneficial or deleterious effects of these 
exposures. Hence, it is suggested that 
the relevant contributing risk factors 
may contradict between Western and 
Asian populations. Biomarker data 
would enable in strengthening the link 
between risk factors and breast cancer 
as shown in epidemiological studies. 
Subdividing breast cancer cases by 
p53 protein expression and searching 
for important patterns in risk factors 
of breast cancer by p53 status could 
help to narrow the search for specific 
p53 mutations. Therefore, this provides 
the impetus for the present study to 
investigate the prevalence of breast 
cancer within epidemiological risk 
factor and association with p53 protein 
expressions in breast cancer tissue 
specimens in premenopausal women.
MATERIALS AND METHODS
DESIGN
Demographic and risk factor profiles 
data were taken from breast cancer 
tissue registries and paraffin embedded 
breast tissue samples were then detected 
for p53 protein expression using 
immunohistochemistry technique. 
The results of p53 protein were then 
compared with risk factor profiles 
available from patient’s registries. 
BREAST CANCER TISSUE 
SAMPLING
A total of 111 breast carcinoma tissue 
samples in paraffin blocks were 
obtained from female patients who 
were diagnosed between June 2005 
and April 2009. The age of the patients 
ranged from 27 to 82 yrs (mean age of 
54 yrs). These paraffin embedded breast 
tissue samples were randomly picked 
from a listed serial number of paraffin 
blocks available from the computed 
registry of the Pathology Laboratory, 
Hospital Tuanku Jaafar, Seremban, 
Negeri Sembilan. A retrospective 
review of the study population was 
available from the patients clinical 
histopathology report (Form Perub. J.P. 
06) which included patient’s age and 
tumour grade status and several other 
risk factor profiles.
DATA COLLECTION AND 
INSTRUMENTS
Demographic data and risk factors 
profile were taken from the patients’ 
histopathology laboratory reports, 
mammography and surgical outpatient 
follow-up case reports.  Based on 
patients address they were residents 
of Negeri Sembilan and being referred 
to Hospital Tuanku Jaafar, Seremban. 
Patient’s age was defined as the age of 
cancer diagnosis.
ETHICAL APPROVAL
Ethical approval was obtained from 
Research Ethics Committee of both 
Universiti Teknologi MARA (UiTM) 
and also MOH Research & Ethics 
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Committee (MREC) of the Ministry of 
Health (MOH) (NMRR 8-16-1771). 
DATA ANALYSIS TECHNIQUE
Immunohistochemical (IHC) Staininig
Paraffin embedded tissue sections, 5 
μm thick, were mounted on silanized 
slides and fixed for 12 mins, The paraffin 
embedded slides were processed 
for IHC staining and evaluated for 
expression of p53. The histological type 
of breast cancer selected randomly 
included invasive and non-invasive 
carcinoma and other benign breast 
diseases. Grading of breast tumour was 
determined using modified Bloom and 
Richardson (1957) criteria  as stated in 
the histopathology report. 
 IHC was performed using the 
DakoCytomation kit (EnVision + 
System-HRP; DakoCytomation 
Denmark A/S, Glostrup, Denmark). 
Paraffin-embedded tissue sections 
from all samples were stained with 
p53, accordingly. Tissue sections were 
de-paraffinized and hydrated prior 
to antigen retrieval by microwave, 
followed by inhibiting the endogenous 
peroxidase activity by 5 mins incubation 
and rinsed with distilled water. Following 
these step, slides were treated for 10 
mins with primary antibodies clone 
DO-7 (N158187, Dako) and optimum 
dilutions were determined according 
to experiments. Slides were then rinsed 
with Tris buffered saline solution (TBS) 
with 0.05% plus Tween 20 (S196630, 
Dako) twice for 3 mins each time. 
Sections were incubated with REAL™ 
Envision Polymer (K4065, Dako) as 
peroxidase labelled polymer to the 
primary antibody for 10 mins each time. 
Antigen was visualized with DAB (3, 3’ 
diaminobexidine) chromogen (K4065, 
Dako) plus diaminobexidine substrate 
buffer (K4065, Dako) preparation and 
counter-stained with haematoxylin 
staining. The incubation protocols 
were conducted at room temperature 
and the tissue sections were carefully 
washed within the incubations series. 
In every experiment, in-house positive 
p53 tissue sections with one positive 
control and one negative control were 
included.
Semiquantitation of p53
For overexpression of p53 protein 
in samples, the staining intensity on 
tissues is scaled between 0 to +3 scores. 
Relatively, tissue section which did not 
exhibit brownish nuclear reactivity in 
tumour cells was recorded as 0. Tissue 
section which occasionally showed 
positive nuclear staining was scored 
as +1, provided the total percentage of 
positivity in tissue section was < 20%. 
Any tissue section which tumour cells 
exhibited positive nuclear staining in 
between 20% - 80% was given score 
of +2. For the +3 score, the scale was 
given to tissue section which depicted 
positive nuclear staining in > 80% 
of tumour cells, and the scales of +1, 
+2, and +3 were recorded as p53+. 
Microscopic examination observed 
using 10X and 40X magnification lens 
field. IHC was confirmed positive if 
the reaction was visualized by Dako 
REALTM DAB+ (3, 3’-diaminobenzidine 
tetrahydrochloride in organic solvent) 
substrate-chromogen solution which 
results in a brown-colored precipitate at 
the antigen site of p53 protein (Figure 1).
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RESULTS
The diagnostic age groups among breast 
cancers was elaborated in Table 1. The 
age at diagnosis ranged between 27 to 
85 yrs. The peak age of diagnosis was 
between 45 and 55 yrs,  with the mean 
age of 54 yrs (S.D 12. 91) while the mode 
age was 46 yrs in the premenopausal 
age group. In Table 1, revealed that the 
majority of p53 (+) protein expression 
was found in the age groups above 41 
yrs. The results indicated that majority 
(n=41/111) who were more than 41 yrs, 
had a positive p53 (+) protein category. 
In addition, minority (n=3/111) of the 
respondents were aged 41 yrs and less 
and also had positive p53 (+) protein 
category (n= 3/111). However, the 
Fishers exact test, indicated that, there 
was no statistically significant correlation 
between age category and p53 protein 
category (χ2 (1) = 0.78, p =0.52), and 
there was no correlation strength 
(Cramer’s V coefficient = 0.08) and also 
not significant (p =0.37) (Table 1).
 To strengthen the correlation 
findings of the p53 protein expression 
and the unmodifiable age as risk factor 
,the estimation study was conducted. 
Table 2 showed the result of risk 
estimate of p53 protein and age group. 
The results reported that the risk factor 
was reduced by 0.66 (or 66.5%) for 
women aged ≤ 41 yrs in expressing 
p53 (+) protein, Risk estimate = 0.66, 
95% confidence interval (CI): 0.24- 
1.79), compared to the women aged 
Figure 1: Positive (IHC) detection of p53 protein (A-D). Tissue with crisp brownish nuclear 
precipitatation of p53 protein overexpression; (A) S0045164, magnification x40, (B) S004776, 
magnification x10. (C) S0048960, magnification x10, and (D) S0047962, magnification x40
(a) (b)
(c) (d)
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> 41 yrs. Therefore,  age group did 
not have any significants (p>0.05) in 
overexpressing  p53 (+) protein. The risk 
estimate showed probability of p53 (+) 
protein being overexpressed in the age 
group less than 41 yrs was 0.66 times 
less likely compared to the age group 
above 41 yrs. 
DISCUSSION
The risks pattern of breast cancer 
among women could be identified by 
the overexpression of p53 in breast 
cancer tissue samples which showed 
the presence of mutant p53. The 
findings indicated that this protein 
would not be degraded or metabolized 
in the tissues and continued to exert 
its original function. The present study 
reported inhibition of the apoptosis 
induction that further triggered the 
uncontrollable growth of tissues that 
resulted in tumour formation. Hence, 
becoming aggressively malignant and 
invasive. The highest percentage of 
expressing p53 (+) in breast cancer 
tissue was found in the age group > 41 
yrs. However, the percentage of p53 (+) 
protein overexpression increased with 
the age group of this study. The majority 
of the respondents (36.9%) of p53 (+) 
overexpression were observed in the 
breast cancer tissue of respondents 
within the age group of > 41 yrs, while 
only (2.7%) of p53 (+) overexpression 
was observed within the age group < 
41 yrs.  
 Our study reported that a total of 
111 participants diagnosed with breast 
cancer between June 2005 and April 
2009, with age groups  within the range 
of 27 to 85 yrs and  mean age of 54 yrs 
upon diagnosed as breast cancer.  Their 
median age was 52 yrs and mode age 
of 46 yrs. Congruently supported  with 
several  studies (Lim et al. 2008; Musa 
et al. 2011). Another study Lim et al. 
Table 1: Participants’ age at diagnosis with p53 protein
Age of diagnosis
N=111
p53 (-)
n (%)
p53 (+)
n (%) %
Less than 41 yrs 
(n=11) 8 (7.2) 3 (2.7) 9.9
More than 41 yrs 
(n=100) 59 (53.2) 41(36.9) 90.1
67(60.4) 44(39.6) 100 %
Summary Results: Fisher’s Exact test, χ2(1) = 0.78, p =0.52, Cramer’s V coefficient = .084, p = 0.37. (χ2 (1) = 0.78, 
p =0.52), χ2 1, n=111= 0.31, p = 0.57, phi = 0 .08.
Table 2: Risk estimate between participant’s age and p53 protein expression
  N p-value Risk estimate (95% C.I) Odd Ratio (95% C.I)
<41 yrs />41 yrs  0.52 1.85(0.46-7.40)
p53(-) 1.23(0.82-1.83)
p53(+ ) 0.66(0.24-1.79)
No of Valid Cases 111
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(2008) had similar results to the present 
study in which  the median age at 
upon diagnosis was 52-53 yrs and  age 
standardized rate (ASR) was between 
the age group 50-59 yrs. 
 The participant’s mode age with 
breast cancer was within 46 yrs. 
According to Hisham & Yip (2004) and 
Toh  et al. (2008)  similar findings were 
found that  nearly 50 % of breast cancer 
cases occurred  in women under the age 
of 50 yrs. Furthermore, Hisham and Yip 
(2004) showed that predominant age 
group  between 40-49 yrs and a high 
proportion were in the advanced stage 
of the disease. In addition, Leong et al. 
(2010) reported a median age of 52 yrs 
for breast cancer occurrence showed a 
salient difference in peak age between 
40-50 yrs in Asian countries and 
between 60-70 yrs in Western countries 
However, a study by Rohan et al. (2006) 
stated that participant’s age  may be a 
prognostic factor in determining the 
probability of increasing metastatic 
potential in breast cancer and it is 
supported with overexpression of p53 
(+) protein that could be  reflected to a 
more advanced stage of progression of 
the breast cancer.
 Significantly, this study may suggest 
that p53 (+) overexpression could be 
an indicator for the likelihood of occult 
alterations existence in breast cancer 
tissues with non-expressing p53 (-) 
protein in a younger age group, whereby 
this predictor may provide a valuable 
indication for earlier detection of breast 
cancer occurrence. Earlier studies by 
Bertheau et al. (2008) and Agrawal et al. 
(2009) showed results ranging from 14-
58% of p53 (+) protein overexpression 
in breast cancer tissues. The findings 
from this present study reported that 
overexpression of p53 (+) protein was 
found in 40% (44/111) of the overall 
breast cancer cases. Notwithstanding, 
there were strong similarities between 
the current study and earlier scientific 
works in terms of the overexpression of 
p53 signified in approximately 14-58 % 
of diagnosed breast cancer cases.
 Adjustment of age in the present 
study would enable to reduce the risk 
factors of age group < 41 yrs to express 
p53 (+) protein. The risk estimation 
showed probability of p53 (+) protein 
being overexpressed in the age group 
less than 41 yrs was 0.66 times less 
likely compared to age group above 41 
yrs. The participants’ age groups were 
related to a non-statistically significant 
increase in the risk of p53 protein. 
The increased odds (OR 1.85) of p53 
(+) protein expression with age groups 
did not reach statistical significant 
as indicated, with (p > 0.05). The 
present study concurred with Erdem 
et al. (2005) who failed to demonstrate 
any association between p53 protein 
expression and age. However, this 
present study, indicated the correlation 
p53 protein and age groups did not 
reach a statistical significance (p > 
0.05), the frequency rate, of p53 (+) 
protein expression among women > 41 
yrs compared to < 41 yrs, was 36.9% 
(41/111) and 2.7% (3/111), respectively. 
 The finding from the present study 
showed that participant’s age groups 
can be a predictor of risk factors for 
breast cancer among older women. 
Congruently supported by previous 
studies Worsham et al. (2007), Etebary 
et al. (2002), and Dupont and Page 
(1989). The alteration and mutation 
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in P53 gene, or overexpression of 
p53 protein as a secondary marker 
in  the mutation pathways would 
likely be considered   as a potential 
prognostic factor or biomarker for 
numerous human malignant tumours, 
particularly breast cancer in which has 
been recognized with worse prognosis 
(Bergh et al. 1995; Kikuchi et al. 2013). 
 Limitation of this study could be 
attributed with the suboptimal methods 
in determination of  p53 status due to 
the small sample size which  did not 
allow more reliable assessment to 
associate with participant’s age factor 
and p53 protein.  However, the analysis 
of p53 protein expression was carried 
out in the absence of knowledge 
regarding case-control status which 
unlikely   contributed to the differential 
bias in the current evaluation of p53.
CONCLUSION
In conclusion with  or without 
overexpression of p53 protein women 
above 41 yrs were at a greater risk 
diagnosed with breast cancer. The 
investigation of p53 (+) overexpression 
in relation to participant’s age group in 
the present study revealed that there 
was fluctuation in the frequency of 
the detection rate of p53 protein. This 
limitation could be contributed by the 
low statistical power of the clinical 
data with reference to the potential 
predictive value of the p53 protein 
which are still conflicting. 
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